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Abstract: Coarctation of the aorta is a form of left ventricular outflow tract obstruction in paediatric
patients that can be presented with either bicuspid (BAV) or normal tricuspid (TAV) aortic
valve. The congenital BAV is associated with hemodynamic changes and can therefore trigger
different molecular remodelling in the coarctation area. This study investigated the proteomic and
phosphoproteomic changes associated with BAV for the first time in neonatal coarctation patients.
Aortic tissue was collected just proximal to the coarctation site from 23 neonates (BAV; n = 10, TAV;
n = 13) that were matched for age (age range 4–22 days). Tissue from half of the patients was frozen
and used for proteomic and phosphoproteomic analysis whilst the remaining tissue was formalin
fixed and used for analysis of elastin content using Elastic Van-Gieson (EVG) staining. A total of
1796 protein and 75 phosphoprotein accession numbers were detected, of which 34 proteins and
one phosphoprotein (SSH3) were differentially expressed in BAV patients compared to TAV patients.
Ingenuity Pathway Analysis identified the formation of elastin fibres as a significantly enriched
function (p = 1.12 × 10−4) due to the upregulation of EMILIN-1 and the downregulation of TNXB.
Analysis of paraffin sections stained with EVG demonstrated increased elastin content in BAV patients.
The proteomic/phosphoproteomic analysis also suggested changes in inositol signalling pathways
and reduced expression of the antioxidant SOD3. This work demonstrates for the first time that
coarcted aortic tissue in neonatal BAV patients has an altered proteome/phosphoproteome consistent
with observed structural vascular changes when compared to TAV patients.
Keywords: aortic coarctation; bicuspid aortic valve; congenital heart disease
1. Introduction
Coarctation of the aorta (CoA) is a common congenital defect whose overall incidence is 5–8% of
all congenital cardiac anomalies [1]. The majority of CoA patients also have a bicuspid aortic valve
(BAV). CoA is a known risk factor for aortic complications including aneurysm formation or aortic
dissection [2,3], and the presence of BAV further increases the risks for CoA patients. Studies have
demonstrated that CoA patients with BAV have increased risk of aortic aneurysm [4], suboptimal
improvement in left ventricular function following repair [5] and greater long-term cardiovascular
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morbidity [6]. The coexistence of CoA and BAV has been demonstrated to significantly affect aortic
blood flow haemodynamics, for example increasing turbulent flow and affecting indices of shear
stress both upstream and downstream of the coarctation [7]; such haemodynamic changes may at
least partly explain the heightened cardiovascular risks in these patients. It is suggested that surgical
correction of CoA repairs the anatomical narrowing but does not address the associated vasculo- and
valvulopathy [8].
BAV can present in different phenotypes which may be related to congenital, genetic, and/or
connective tissue abnormalities [9]. Discrimination between BAV subtypes may potentially provide
clinical and prognostic information in patients with coarctation of the aorta [10]. Interestingly, induced
loss-of-function in murine Nos3 (which encodes endothelial nitric oxide synthase type 3) or in human
GATA5 (which encodes a Zn-finger transcription factor) have both been reported to associate with BAV
phenotype [11,12]. Moreover, NOTCH1 mutations are associated with cardiovascular malformations,
and many of the patients with CoA tend to have mutations in the NOTCH1 gene [13].
However, a comparison of the whole proteome of CoA patients with and without BAV has not been
performed. Studies using tissue from patients undergoing aortic aneurism surgery have demonstrated
significant differences in the proteome of BAV patients compared to TAV patients (e.g., [14]), however
a similar analysis has not been applied to neonatal CoA patients. The effects of factors (such as altered
blood flow haemodynamics) which may affect the aortic proteome and phosphoproteome are likely
to still be evolving in the weeks after birth. In this study we therefore compared the proteome and
phosphoproteome of aortic tissue from very young (less than three weeks old) CoA patients with and
without BAV, thus providing a unique insight into the vascular molecular remodelling occurring in
neonatal CoA patients as a result of congenital valve malformation.
2. Experimental Section
2.1. Patients and Tissue Collection
Tissue was collected just proximal to the coarctation site from neonatal patients undergoing congenital
surgery including repair of the aortic coarctation. The study was conducted in accordance with the
declaration of Helsinki, and the protocol was approved by the North Somerset and South Bristol Research
Ethics Committee (REC 07/H0106/172). Full informed consent was obtained from parents prior to
admission for operation. Aortic tissue from the coarctation area of half the patients was snap frozen in
liquid nitrogen before being stored at −80 ◦C (TAV: n = 5, aged 10 ± 2 days (mean ± SEM). BAV: n = 7,
aged 10 ± 2 days). Aortic tissue from the remainder of the patients was fixed in 10% formalin before being
transferred to PBS for storage (TAV: n = 5, aged 7 ± 1 days. BAV: n = 6, aged 9 ± 2 days).
2.2. Sample Preparation
Proteins were extracted in radio-immuno-precipitation assay (RIPA) buffer (1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, in PBS) containing phosphatase and protease inhibitors, and quantified using
the Bradford assay. Aliquots of 100 µg of 10 samples per experiment were digested with trypsin (2.5 µg
trypsin per 100 µg protein; 37 ◦C, overnight), labelled with Tandem Mass Tag (TMT) 10Plex reagents
according to the manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, LE11 5RG, UK),
and the labelled samples pooled.
For the total proteome analysis, aliquots of 50 µg of the pooled sample were evaporated to
dryness and re-suspended in buffer A (20 mM ammonium hydroxide, pH 10) prior to fractionation
by high pH reversed-phase chromatography using an UltiMate 3000 liquid chromatography system
(Thermo Fisher Scientific). The sample was loaded onto an XBridge BEH C18 Column (130 Å, 3.5 µm,
2.1 × 150 mm, Waters, UK) in buffer A and peptides eluted with an increasing gradient of buffer B
(20 mM Ammonium Hydroxide in acetonitrile, pH 10) from 0–95% over 60 min. The resulting fractions
were evaporated to dryness and re-suspended in 1% formic acid prior to analysis by nano-LC MSMS
using an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific).
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For the phosphoproteome analysis, the remainder of the TMT-labelled pooled sample was
evaporated to dryness and subjected to TiO2-based phosphopeptide enrichment according to the
manufacturer’s instructions (Pierce). The phospho-enriched sample was evaporated to dryness and
then re-suspended in 1% formic acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion
Tribrid mass spectrometer (Thermo Fisher Scientific).
2.3. Nano-LC Mass Spectrometry
High pH RP fractions (total proteome analysis) or the phospho-enriched fraction
(phospho-proteome analysis) were further fractionated using an Ultimate 3000 nano-HPLC system in
line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). In brief, peptides in 1%
(vol./vol.) formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific).
After washing with 0.5% (vol./vol.) acetonitrile 0.1% (vol./vol.) formic acid, peptides were resolved on
a 250 mm × 75 µm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over
a 150 min organic gradient, using seven gradient segments (1–6% solvent B over 1 min, 6–15% B
over 58 min, 15–32% B over 58 min, 32–40% B over 5 min, 40–90% B over 1 min, held at 90% B for
6 min and then reduced to 1% B over 1 min) with a flow rate of 300 nL·min−1. Solvent A was 0.1%
formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized
by nano-electrospray ionization at 2.0 kV using a stainless-steel emitter with an internal diameter of
30 µm (Thermo Scientific) and a capillary temperature of 275 ◦C.
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by
Xcalibur 2.0 software (Thermo Scientific) and operated in data-dependent acquisition mode using
an SPS-MS3 workflow. FTMS1 spectra were collected at a resolution of 120,000, with an automatic
gain control (AGC) target of 200,000 and a maximum injection time of 50 ms. The Top N most intense
ions were selected for MS/MS. Precursors were filtered according to charge state (to include charge
states 2–7) and with mono-isotopic precursor selection. Previously interrogated precursors were
excluded using a dynamic window (40 s +/− 10 ppm). The MS2 precursors were isolated with a
quadrupole mass filter set to a width of 1.2 m/z. ITMS2 spectra were collected with an AGC target of
5000, max injection time of 120 ms and CID collision energy of 35%.
For FTMS3 analysis, the Orbitrap was operated at 60,000 resolution with an AGC target of 50,000
and a max injection time of 120 ms. Precursors were fragmented by high-energy collision dissociation
(HCD) at normalised collision energy of 55% to ensure maximal TMT reporter ion yield. Synchronous
Precursor Selection (SPS) was enabled to include up to five MS2 fragment ions in the FTMS3 scan.
2.4. Data Processing and Analysis
The raw data files were processed and quantified using Proteome Discoverer software
version 1.4 (Thermo Scientific) and peptide sequences searched against the Uniprot Human database
(134,169 sequences) using the SEQUEST algorithm. Peptide precursor mass tolerance was set at 10 ppm,
and MS/MS tolerance was set at 0.6 Da. Search criteria included oxidation of methionine (+15.9949) as
a variable modification and carbamido-methylation of cysteine (+57.0214) and the addition of the TMT
mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. For the phosphoproteome
analysis, phosphorylation of serine, threonine and tyrosine (+79.966) were also included as variable
modifications. Searches were performed with full tryptic digestion and a maximum of one missed
cleavage was allowed. The reverse database search option was enabled and all peptide data was
filtered to satisfy false discovery rate (FDR) of 5%.
Any proteins or phosphoproteins with more than one missing value per sample group were
excluded from the analysis [15]. Putative uncharacterized proteins or proteins with either accession
numbers representing cDNA with weak similarity were also excluded. For the proteomics data,
values for each of the proteins identified are presented as a ratio to the internal standard (a pool of all
samples) and represent the median of the measured peptide(s) for each protein. Fold changes between
BAV and TAV patients were calculated, and high-fold differences (fold decrease/increase greater than
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±1.3 identified. The value of 1.3 was used as a cut off as it has previously been used in other, similar
studies, for example [16]. Significant changes were determined by an unpaired Student’s t-test (p < 0.05
being significant). Volcano plots were created by plotting log2 (fold difference) on the horizontal axis
and −log10 (p-value) on the vertical axis.
Gene ontology (GO) enrichment analysis of differentially expressed proteins was performed
using QuickGO software. Differentially expressed proteins and phosphoproteins were inputted into
Ingenuity Pathway Analysis software (IPA version 46901286, Qiagen, Aarhus, Denmark) to determine
significantly enriched canonical pathways, diseases and functions (p-value of overlap calculated by
Fisher’s exact test right tailed).
2.5. Elastin Staining Analysis
Fixed aortic tissue was embedded in paraffin and sectioned at 5 µm. Three to five sections from
each patient were stained with Elastic Van-Gieson stain (EVG). Elastin density was measured at 40×
magnification on four randomly selected areas of each section using ImageJ software (National Institute
of Health, Bethesda, MD, USA, Version 1.46). The results were analysed with an unpaired Student’s
t-test, significance was accepted when p < 0.05.
3. Results
A total of 1796 protein accession numbers were detected, of which 34 were significantly differentially
expressed between BAV and TAV patients (Figure 1A, Table 1). Of these, two proteins (TNC and
EMILIN1) were significantly up-regulated in BAV patients compared to TAV patients, whilst the
remainder were significantly down regulated.
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Figure 1. Volcano plot f proteins (A) and phos t ins (B) quant fied i neonatal patients with
bicuspid (BAV) verses patients with normal tricuspid (TAV). Each point represent the log2 (fold change)
betwee the groups plotted against the ssociated significance of this hange. Proteins significantly
altered (±1.3 fold change, p < 0.05) are shown in the grey shaded areas. TNXB: Tenascin-X; PLCD1:
Phosphoinositide phospholipase C; SOD3: Extracellular superoxide dismutase 3; EMILIN-1: elastin
microfibril interfacer 1; TNC: Tenascin C; SSH3: Protein phosphatase slingshot homolog 3; BAV:
bicuspid aortic valve; TAV: tricuspid aortic valve.
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Table 1. Proteins differentially (fold decrease/increase > ±1.3)) and significantly (p < 0.05) expressed in coarcted aorta from neonatal BAV patients compared to
neonatal TAV patients.
Accession # Gene ID Description
Mean SEM Fold Change
(BAV/TAV)
p-Value log2 (Fold
Change)
−log10
(p-Value)BAV TAV BAV TAV
F5H7R9 PTMS Parathymosin (Fragment) 0.52 1.49 0.13 0.47 0.35 0.045 −1.52 1.35
A0A024R1R8 hCG_2014768 HCG2014768, isoform CRA_a 1.79 4.47 0.4 0.79 0.40 0.008 −1.32 2.10
Q15847 ADIRF Adipogenesis regulatory factor 0.50 1.24 0.09 0.13 0.40 0.001 −1.31 3.29
A0A087WY58 NEK3 Serine/threonine-protein kinase Nek3 4.09 9.67 1.67 0.79 0.42 0.024 −1.24 1.61
P23468 PTPRD Receptor-type tyrosine-protein phosphatase delta 2.63 6.00 0.59 0.78 0.44 0.006 −1.19 2.24
A0A087WWA5 TNXB Tenascin-X 0.73 1.58 0.11 0.39 0.46 0.036 −1.11 1.45
A0A087WYN4 TTC25 Tetratricopeptide repeat protein 25 0.49 1.05 0.11 0.22 0.47 0.033 −1.09 1.48
B4DVR4 - cDNA, FLJ60912, highly similar to Vinexin 1.91 3.81 0.35 0.82 0.50 0.039 −1.00 1.41
Q96CN7 ISOC1 Isochorismatase domain-containing protein 1 1.26 2.45 0.29 0.34 0.51 0.023 −0.96 1.63
P51610 HCFC1 Host cell factor 1 0.99 1.91 0.17 0.32 0.52 0.020 −0.95 1.70
O76070 SNCG Gamma-synuclein 0.67 1.30 0.18 0.18 0.52 0.035 −0.95 1.46
E9PNK6 TPD52L1 Tumour protein D53 1.43 2.72 0.29 0.35 0.53 0.018 −0.93 1.75
B7Z650 - cDNA, FLJ58685, highly similar to Homo sapiens echinoderm microtubuleassociated protein like 1 1.15 2.17 0.25 0.40 0.53 0.043 −0.92 1.37
H7C4C5 MAP4 Microtubule-associated protein (Fragment) 0.87 1.63 0.20 0.26 0.53 0.040 −0.90 1.40
O76024 WFS1 Wolframin 1.29 2.36 0.25 0.33 0.54 0.024 −0.88 1.62
Q4ZG81 FLJ20701 Putative uncharacterized protein FLJ20701 (Fragment) 0.92 1.66 0.22 0.16 0.55 0.031 −0.86 1.51
Q9Y4G6 TLN2 Talin-2 1.04 1.88 0.20 0.28 0.55 0.030 −0.86 1.52
A0A024RAR8 ARTS-1 Type 1 tumour necrosis factor receptor shedding aminopeptidase regulator,isoform CRA-a 0.87 1.58 0.14 0.18 0.55 0.011 −0.86 1.97
Q59GL1 - Synaptotagmin binding, cytoplasmic RNA interacting protein variant (Fragment) 2.65 4.8 0.59 0.78 0.55 0.048 −0.86 1.31
A8K8F9 PLCD1 Phosphoinositide phospholipase C 0.81 1.47 0.15 0.18 0.55 0.021 −0.85 1.69
B1AJY5 PSMD10 26S proteasome non-ATPase regulatory subunit 10 1.62 2.88 0.35 0.35 0.56 0.032 −0.83 1.50
BD4L66 - cDNA FLJ56297, highly similar to Rattus norvegicus ubiquitin-conjugatingenzyme E2Z (PUTATIVE) (Ube2z) 2.04 3.60 0.36 0.54 0.57 0.032 −0.82 1.49
F2Z2V0 CPNE1 Copine-1 (Fragment) 0.86 1.45 0.11 0.25 0.59 0.038 −0.75 1.42
Q9H7C9 AAMDC Mth938 domain-containing protein 1.39 2.31 0.25 0.16 0.60 0.020 −0.73 1.71
O95865 DDAH2 N(G), N(G)-dimethylarginine dimethylaminohydrolase 2 1.57 2.60 0.32 0.29 0.61 0.047 −0.72 1.33
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Table 1. Cont.
Accession # Gene ID Description
Mean SEM Fold Change
(BAV/TAV)
p-Value log2 (Fold
Change)
−log10
(p-Value)BAV TAV BAV TAV
Q5T6V5 C9orf64 UPF0553 protein C9orf64 1.11 1.80 0.19 0.24 0.62 0.047 −0.70 1.33
P01034 CST3 Cystatin-C 1.55 2.51 0.27 0.31 0.62 0.041 −0.69 1.39
Q7Z4V5 HDGFRP2 Hepatoma-derived growth factor-related protein 2 1.11 1.78 0.20 0.21 0.62 0.044 −0.69 1.36
B3KM48 - cDNA, FLJ10286fis, clone HEMBB1001384, highly similar to COP9 signalosomecomplex subunit 4 1.52 2.41 0.25 0.32 0.63 0.049 −0.67 1.31
P62312 LSM6 U6 snRNA-associated Sm-like protein LSm6 1.24 1.89 0.22 0.13 0.65 0.043 −0.61 1.37
A0A087WYV5 SLIT2 Slit homolog 2 protein 1.25 1.88 0.06 0.09 0.67 <0.0002 −0.58 3.90
P08294 SOD3 Extracellular superoxide dismutase (Cu-Zn) 0.87 1.3 0.08 0.18 0.67 0.035 −0.58 1.46
A0A024R884 TNC Tenascin C (Hexabrachion), isoform CRA_a 1.88 0.68 0.29 0.15 2.75 0.010 1.46 2.02
A0A0C4DFX3 EMILIN1 elastin microfibril interfacer 1 2.90 1.64 0.39 0.27 1.76 0.038 0.82 1.42
Proteins that are found at higher levels in BAV are shown in bold italics at the bottom of the table. #; number.
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The differentially expressed proteins were functionally classified by Gene Ontology analysis under
the three main categories of GO analysis (i.e., biological process, cellular component and molecular
function). Protein binding and superoxide dismutase activity were the most represented GO terms
within molecular functions, whilst cytoplasm and protein stabilization were the most represented
cellular component and biological process respectively (Figure 2). Superoxide radical degeneration
was also identified by IPA Ingenuity pathway analysis as one of two significantly (p < 0.05) enriched
canonical pathways, the other being D-myo-inositol (1,4,5) trisphosphate biosynthesis (Table 2).
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Table 3 sho s the top five most significantly enriched diseases or functions overall, as well as all
significantly enriched diseases and functions falling under the IPA category ‘Cardiovascular system
Development and Function’. Aortic valve morphogenesis was not surprisingly identified as being
highly significant (p = 3.44 × 10− ). Elastin fibre formation was the second most significantly enriched
function overall (p = 1.12 × 10−4). The two proteins associated with this change were TNXB and
EMILIN-1, the latter being one of only two proteins upregulated in BAV patients compared to TAV
patients. Histological measurements in separate cohorts of patients confirmed a significant difference
in elastin content between the t o groups, with greater elastin content in the aortas of BAV patients
(Figure 3).
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Table 3. Diseases and functions with enriched protein expression for significantly altered total protein
levels in aortic tissue of BAV patients compared to TAV patients.
IPA Disease or Function p-Value Molecules # Molecules
Overall
Morphology of hippocampal neurons 9.13 × 10−5 CST3, SYNCRIP 2
Formation of elastin fibres 1.12 × 10−4 EMILIN1, TNXB 2
Secondary Tumour 1.41 × 10−4 ADIRF, CST3, MAP4, PSMD10,PTPRD, SLIT2, SNCG, SOD3, TNC 9
Migration of oligodendrocyte precursor cells 1.58 × 10−4 SLIT2, TNC 2
Morphogenesis of aortic valve 3.44 × 10−4 EMILIN1, SLIT2 2
Cardiovascular System Development and Function
Morphogenesis of aortic valve 3.44 × 10−4 EMILIN1, SLIT2 2
Relaxation of carotid artery 1.01 × 10−2 SOD3 1
Angiogenesis 1.58 × 10−2 CST3, EMILIN1, ERAP1, PLCD1,SLIT2, TNC 6
Relaxation of aorta 2.02 × 10−2 SOD3 1
Abnormal morphology of tunica media 2.16 × 10−2 CST3 1
Vasculogenesis 2.43 × 10−2 CST3, ERAP1, PLCD1, SLIT2, TNC 5
Vascularization of placenta 2.44 × 10−2 PLCD1 1
Abnormal morphology of aortic arch 4.27 × 10−2 CST3 1
The top half of the table shows the top five most significant diseases and functions overall. The bottom half of the
table shows all the significant diseases and functions under the IPA category ‘Cardiovascular System Development
and Function’. #; number.
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Abnormal morphology of tunica media 2.16 × 10−2 CST3 1 
Vasculogenesis 2.43 × 10−2 
CST3, ERAP1, PLCD1, 
SLIT2, TNC 
5 
Vascularization of placenta 2.44 × 10−2 PLCD1 1 
Abnormal morphology of aortic arch 4.27 × 10−2 CST3 1 
The top half of the table shows the top five most significant diseases and functions overall. The bottom 
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‘Cardiovascular Syst m Development and Function’. #; number. 
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Figure 3. Elastin content in TAV vs. BAV patients. * p < 0.05, Student’s t-test. Representative elastin
staining from TAV (left) and BAV (right) patients. Scale bars represent 40 µm.
A total of 75 phosphorylated proteins were identified, some with multiple phosphorylation sites,
resulting in 90 phosphorylation site matches. Only one, protein phosphatase slingshot homolog 3,
was differentially expressed between BAV patients and TAV patients (Table 4), resulting in significant
enrichment in a number of pathways involved in inositol metabolism (Table 5).
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Table 4. Significantly changed phosphoproteins in the aortas of neonatal BAV patients compared to TAV patients.
Accession # Gene ID Protein Name
Protein
Phosphosite
Mean SEM Fold Change
(BAV/TAV)
p-Value log2 (Fold Change) −log10 (p-Value)
BAV TAV BAV TAV
C9JUG3 SSH3 Protein phosphataseslingshot homolog 3 Serine 3 1.11 1.82 0.18 0.2 0.61 2.4 × 10−2 −0.72 1.619
Protein phosphosite: the number indicates the position of the modification in the protein.
Table 5. Canonical pathway analysis: pathways likely to be altered by SSH3 phosphorylation.
IPA Canonical Pathway p-Value
D-myo-inositol (1,4,5,6)-tetrakisphosphate Biosynthesis 6.54 × 10−3
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 6.54 × 10−3
3-phosphoinositide Degradation 7.17 × 10−3
D-myo-inositol-5-phosphate Metabolism 7.35 × 10−3
3-phosphoinositide Biosynthesis 9.17 × 10−3
Actin Cytoskeleton Signalling 1.02 × 10−2
Superpathway of Inositol Phosphate Compounds 1.08 × 10−2
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4. Discussion
To the best of our knowledge, this is the first comparison of the neonatal aortic proteome of
CoA patients with BAV compared to CoA patients with a normal valve. Although the anatomy of
the coarcted aorta appears the same in the two groups of patients, this study provides evidence for
proteomic and histological differences associated with the presence of an abnormal valve.
4.1. Proteomic and Structural Analysis Identify Changes in Elastin as the Main Structural Aortic Alteration
Associated with BAV
Prostaglandin E1 is often administered to neonatal CoA patients to maintain the patency of
the ductus arteriosis, hence reducing the total velocity of blood flow through the aortic valve [17].
However, it has been suggested that the coexistence of CoA and BAV increases turbulent flow and
shear stress both upstream and downstream of the coarctation area compared to patients with CoA
alone [7]. Such changes in blood haemodynamics may, in turn, cause aortic molecular and structural
remodelling. Two of the proteins which demonstrated significantly altered expression in this study
were EMILIN-1, whose expression was upregulated in BAV patients compared to TAV patients, and
TENASCIN-X, whose expression was downregulated in BAV patients. Canonical pathway analysis
suggested that these changes indicate significant differences in elastin fibre formation between the two
groups, and histological analysis in a separate subset of patients did indeed demonstrate significantly
increased elastin content in BAV patients compared to TAV patients.
EMILIN-1 is a glycoprotein which associates with elastic fibres at the interface of elastin and
microfibrils. It is known to be involved in the creation of molecular interactions between elastic fibre
components and therefore to play an important role in elastogenesis [18]. This is confirmed by the
finding that EMILIN-1 deficiency causes elastin fragmentation [18,19], thus the observed increase in
expression of EMILIN-1 in BAV patients in this study is consistent with greater elastin density.
TENASCIN-X is an extracellular matrix protein whose expression was downregulated in BAV
patients. A deficiency in TENASCIN-X protein has been reported to be one cause of Ehlers-Danlos
syndrome (EDS), and patients with this form of EDS can suffer from abnormal dermal elastin fibre
morphology which is suggested to be caused by altered elastin assembly and stability rather than
altered degradation of elastin [20]. The fact that elastin fibre abnormalities are not present in other
forms of EDS has been purported as evidence that the elastin fibre deficiencies are a direct result of the
deficiency of the TENASCIN-X protein [21].
Interestingly, another protein from the TENASCIN family, TENASCIN-C was also differentially
expressed between the two patient groups and was the only other protein besides EMILIN-1 to be
upregulated in BAV patients compared to TAV patients. Previous studies have also found concurrent
increases in TENASCIN-C and elastin, for example in patients with lung fibrosis [22]. However,
other studies have found conflicting results, for example one study demonstrated that increases in
TENASCIN-C are associated with increased elastin calcification and degradation [23]. The precise
nature of any causative relationships between the TENASCIN-C and elastin is therefore unclear and
may differ between organs.
Elastin is an important structural component of the aorta, creating elasticity in the walls of
the vessel and therefore allowing buffering of the pressure changes generated by the cardiac cycle.
Experiments using cultured human smooth muscle cells have demonstrated that elastin synthesis
can be affected by changes in strain or application of pulsatile flow [24,25]. A study in adult BAV
patients demonstrated greater elastin degradation in aortic areas with increased wall shear stress
compared to adjacent areas with normal wall shear stress in the same patient [26]. Thus, it is possible
that haemodynamic changes resulting from the presence of BAV are responsible for the correlation
between elastin abnormalities and the presence of BAV observed in the current study.
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4.2. Inositol and Oxidative Stress Signalling Pathways are Altered in BAV Patients
The enzyme superoxide dismutase 3 (SOD3) was significantly under-expressed in the aortas of
BAV patients compared to TAV patients. In adult humans, the BAV phenotype has been shown to
associate with increased levels of aortic oxidative stress [27]. One explanation suggested for this is that
mechanical stretch of blood vessels is known to result in increased superoxide production via various
pathways including activation of NADPH oxidase, activation of xanthine oxidase and an increase
in eNOS signalling [28]. Interestingly, despite the presence of increased oxidative stress in aortas of
adults with the BAV phenotype, the tissues fail to show increased superoxide dismutase activity—total
SOD activity was demonstrated to be similar between BAV and TAV patients [27], whilst multiple
studies have demonstrated SOD3 expression to be reduced in adult BAV patients compared to TAV
patients [29,30]. Data from the current study indicates, to the best of our knowledge for the first time,
that SOD3 expression is also associated with BAV in neonatal CoA patients.
Changes suggestive of altered inositol signalling correlating with the presence of BAV were also
found in both the proteomic and phosphoproteomic analyses. Inositide molecules are involved in many
aspects of cellular signalling within the cardiovascular system and have been linked to modulation of
aortic structure and aortic aneurysm formation [31]. In the current study, Phospholipase C (PLC) was
significantly downregulated in BAV patients, whilst altered phosphorylation of SSH3 affects many
inositol signalling pathways. Few studies have investigated changes in inositol signalling associated
with BAV, although changes in the abundance of different isoforms of protein kinase C (PKC), which
interacts with inositol signalling molecules, have been described in adult BAV patients [32].
Limitations of the study include the fact that we do not have aortic tissue from healthy neonates,
clearly this would be the ideal control group but is very difficult if not impossible to obtain. It would
also have been ideal to carry out both the proteomic and histological analyses in every patient, however
unfortunately the size of tissue samples which can be obtained from neonatal patients is extremely
small, making it very difficult to perform both analyses for every patient. Slight regional differences
in the exact location of the tissue collection may unfortunately have introduced variation into our
analyses; regional differences in molecular remodelling in CoA patients could be a focus of future
studies. Additionally, it would have been beneficial to validate the changes in protein expression using
Western blotting.
5. Conclusions
Neonatal CoA patients with a bicuspid aortic valve show less improvement in ventricular function
following repair and greater long-term cardiovascular risks compared to CoA patients with a normal,
tricuspid aortic valve [4–6]. This study found significant differences in the aortic proteome of neonatal
CoA patients dependent on the morphology of the aortic valve. Compared to patients with a normal
valve, BAV patients demonstrated increased elastin content, changes in the expression of proteins
involved in response to oxidative stress, and alterations in proteins involved in inositol signalling
pathways. Whilst previous studies which have compared BAV and TAV patients have all taken place
in adults, this study is the first to investigate the effects of a bicuspid aortic valve in neonatal children
with CoA. Improved understanding of molecular and structural remodelling of the aorta in neonatal
patients with BAV will help in the design of long-term therapeutic targets.
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